Last updated: 11.06.2019
ALRN-6924 is a first-in-class, stabilized cell-permeating alpha-helical peptide that mimics the p53 tumor suppressor protein to disrupt p53’s interactions with its endogenous inhibitors, MDMX and MDM2.
Our clinical development program is focused on a Phase 2a clinical trial combining Aileron’s lead product candidate ALRN-6924 and Pfizer’s palbociclib (IBRANCE®), for the treatment of patients with MDM2-amplified cancers, and a Phase 1b/2 clinical trial to evaluate ALRN-6924 as a myelopreservative agent to protect against chemotherapy-induced toxicities. Our first myelopreservation clinical trial is in small cell lung cancer patients treated with the chemotherapy topotecan.
Amplification of the gene encoding MDM2, an endogenous inhibitor of the p53 tumor suppressor protein, is an oncogenic event found in 2-4% of all cancers. In November 2018, we announced a collaboration with Pfizer to evaluate the combination of ALRN-6924 and palbociclib in patients with MDM2-amplified solid tumors.
Chemotherapies used to treat cancer patients can cause toxicities in normal tissues and organs, thereby limiting the dose and schedule of these drugs and reducing their efficacy. This is because these drugs lack specificity for cancer cells and can damage normal, healthy cells. We believe that treatment of patients with ALRN-6924 can reduce the toxic effects of chemotherapy in the bone marrow while having no adverse effect on the anti-cancer activity of chemotherapy against p53-mutant tumor cells.